1.
Cancer Research and Treatment
; : 88-91, 2007.
Artigo
em Inglês
| WPRIM
| ID: wpr-195935
RESUMO
Rituximab is a human/murine chimeric anti-CD20 mono- clonal antibody used to treat CD20-positive B-cell non- Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymp-tomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non- Hodgkin's lymphoma.